Skip to main content

Home/ Dr. Goodyear/ Group items tagged II

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

High-Dose Vitamin C for Cancer Therapy - PMC - 0 views

www.ncbi.nlm.nih.gov/...PMC9231292

vitamin C cancer

shared by Nathan Goodyear on 27 Jul 22 - No Cached
  • diabetes [8], atherosclerosis [9], the common cold [10], cataracts [11], glaucoma [12], macular degeneration [13], stroke [14], heart disease [15], COVID-19 [16], and cancer.
  • 1–5% of the Vit-C inside the human cells
  • interaction between Fe(II) and H2O2 produces OH− through the Fenton reaction
  • ...35 more annotations...
  • metabolic activity, oxygen transport, and DNA synthesis
  • Iron is found in the human body in the form of haemoglobin in red blood cells and growing erythroid cells.
  • macrophages contain considerable quantities of iron
  • iron is taken up by the majority of cells in the form of a transferrin (Tf)-Fe(III) complex that binds to the cell surface receptor transferrin receptor 1 (TfR1)
  • excess iron is retained in the liver cells
  • the endosomal six transmembrane epithelial antigen of the prostate 3 (STEAP3) reduces Fe(III) (ferric ion) to Fe(II) (ferrous ion), which is subsequently transferred across the endosomal membrane by divalent metal transporter 1 (DMT1)
  • labile iron pool (LIP)
  • LIP is toxic to the cells owing to the production of massive amounts of ROS.
  • DHA is quickly converted to Vit-C within the cell, by interacting with reduced glutathione (GSH) [45,46,47]. NADPH then recycles the oxidized glutathione (glutathione disulfide (GSSG)) and converts it back into GSH
  • Fe(II) catalyzes the formation of OH• and OH− during the interaction between H2O2 and O2•− (Haber–Weiss reaction)
  • Ascorbate can efficiently reduce free iron, thus recycling the cellular Fe(II)/Fe(III) to produce more OH• from H2O2 than can be generated during the Fenton reaction, which ultimately leads to lipid, protein, and DNA oxidation
  • Vit-C-stimulated iron absorption
  • reduce cellular iron efflux
  • high-dose Vit-C may elevate cellular LIP concentrations
  • ascorbate enhanced cancer cell LIP specifically by generating H2O2
  • Vit-C produces H2O2 extracellularly, which in turn inhibits tumor cells immediately
  • tumor cells have a need for readily available Fe(II) to survive and proliferate.
  • Tf has been recognized to sequester most labile Fe(II) in vivo
  • Asc•− and H2O2 were generated in vivo upon i.v Vit-C administration of around 0.5 g/kg of body weight and that the generation was Vit-C-dose reliant
  • free irons, especially Fe(II), increase Vit-C autoxidation, leading to H2O2 production
  • iron metabolism is altered in malignancies
  • increase in the expression of various iron-intake pathways or the downregulation of iron exporter proteins and storage pathways
  • Fe(II) ion in breast cancer cells is almost double that in normal breast tissues
  • macrophages in the cancer microenvironment have been revealed to increase iron shedding
  • Advanced breast tumor patients had substantially greater Fe(II) levels in their blood than the control groups without the disease
  • increased the amount of LIP inside the cells through transferrin receptor (TfR)
  • Warburg effect, or metabolic reprogramming,
  • Warburg effect is aided by KRAS or BRAF mutations
  • Vit-C is supplied, it oxidizes to DHA, and then is readily transported by GLUT-1 in mutant cells of KRAS or BRAF competing with glucose [46]. DHA is quickly converted into ascorbate inside the cell by NADPH and GSH [46,107]. This decrease reduces the concentration of cytosolic antioxidants and raises the intracellular ROS amounts
  • increased ROS inactivates glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
  • ROS activates poly (ADP-ribose) polymerase (PARP), which depletes NAD+ (a critical co-factor of GAPDH); thus, further reducing the GAPDH associated with a multifaceted metabolic rewiring
  • Hindering GAPDH can result in an “energy crisis”, due to the decrease in ATP production
  • high-dose Vit-C recruited metabolites and increased the enzymatic activity in the pentose phosphate pathway (PPP), blocked the tri-carboxylic acid (TCA) cycle, and increased oxygen uptake, disrupting the intracellular metabolic balance and resulting in irreversible cell death, due to an energy crisis
  • mega-dose Vit-C influences energy metabolism by producing tremendous amounts of H2O2
  • Due to its great volatility at neutral pH [76], bolus therapy with mega-dose DHA has only transitory effects on tumor cells, both in vitro and in vivo.
Nathan Goodyear

Endogenous Sex Hormones and the Development of Type 2 Diabetes in Older Men and Women: ... - 0 views

care.diabetesjournals.org/...55

type II diabetes Testosterone men women risk SHBG diabetes hormone hormones

shared by Nathan Goodyear on 13 May 14 - No Cached
  • Nathan Goodyear on 13 May 14
     
    A prospective study of aging men and women in the development risk of type II diabetes.  The sexes bring significant differences.  In men, low Testosterone predicts the development of type II diabetes.  In women, just the opposite is seen--high Testosterone levels and low SHBG are most predictive of type II diabetes risk.
Nathan Goodyear

Gut microbe levels are linked to type 2 diabetes and obesity -- ScienceDaily - 0 views

www.sciencedaily.com/...140623141842.htm

gut microbiota dysbiosis diabetes obesity

shared by Nathan Goodyear on 25 Jun 14 - No Cached
  • Nathan Goodyear on 25 Jun 14
     
    Individuals with obesity and type II Diabetes been found to have significantly different gut bacteria populations compared to healthy individuals.  This is not new information.  The firmicutes:bacteroidetes ratio has been long known to be elevated in obese individuals vs those that are lean.  The question here is cause and effect.  Is the change in the bacterial population leading to obesity and type II diabetes?  Or is diabetes and obesity leading to changes in the bacterial population?  A heavy-laden carb diet is know to lead to a change to a more unhealthy gut bacterial population--maybe it is just a product of diet?  Maybe it is effected by vaginal delivery vs cesarean delivery?  Maybe breast feeding plays a role.  Maybe, all the above is required. The point is that the cause of obesity and type II diabetes may have its origins deep, deep in the...well you know. http://ow.ly/yqDML 
Nathan Goodyear

Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyper... - 0 views

jcem.endojournals.org/...668

type II DM type II diabetes diabetes insulin mortality rate mortality

shared by Nathan Goodyear on 21 Feb 13 - No Cached
  • Nathan Goodyear on 21 Feb 13
     
    not sure if I posted this previously, but new study finds that insulin should be the last thing given to a type II diabetic.  Insulin doubles mortality rate.
Nathan Goodyear

ScienceDirect.com - Environmental Research - Adipose tissue concentrations of persisten... - 0 views

www.sciencedirect.com/...S0013935112003210

diabetes type II DM type II diabetes environmental toxins PCB's organochlorine pesticides polychlorinated biphenyls

shared by Nathan Goodyear on 08 Feb 13 - No Cached
  • Nathan Goodyear on 08 Feb 13
     
    PCBs and organochlorine pesticides associated with increased risk of type II diabetes
Nathan Goodyear

Effects of progestin-only long-acting contraception on metabolic markers in obese women - 0 views

www.contraceptionjournal.org/...abstract

progestin contraception type II DM type II diabetes diabetes

shared by Nathan Goodyear on 08 Feb 13 - No Cached
  • Nathan Goodyear on 08 Feb 13
     
    Progestin is not a good synthetic progesterone anyways; but this study shows that progestin in obese women in the form of contraception, increases the risk of type II DM.
Nathan Goodyear

Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyper... - 0 views

jcem.endojournals.org/...668.abstract

diabetes type II DM type II diabetes insulin mortality cancer cmoplications

shared by Nathan Goodyear on 08 Feb 13 - No Cached
  • Nathan Goodyear on 08 Feb 13
     
    Insulin therapy in people with type II diabetes shown to increase complications, cancer, and mortality.  The reason?  Insulin is not the problem.  Treat the cause.  Diabetes can not be properly managed without dietary changes and weight loss.
Nathan Goodyear

The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance --... - 1 views

www.andrologyjournal.org/...23

low T testosterone insulin resistance IR type II diabetes DM metabolic syndrome fat mortality

shared by Nathan Goodyear on 11 Feb 12 - No Cached
  • Nathan Goodyear on 11 Feb 12
     
    low Testosterone associated with insulin resistance, type II diabetes, metabolic syndrome, and increased fat.  These will all translate to increased mortality.
Nathan Goodyear

Predictive parameters of accelerated muscle loss in... [Am J Med. 2014] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...24524994

muscle Total Testosterone free T type II diabetes type II DM parathyroid PTH

shared by Nathan Goodyear on 15 Feb 14 - No Cached
  • Nathan Goodyear on 15 Feb 14
     
    Study looked at muscle loss in older men and found that low activity, type II diabetes, low Total Testosterone and low free Testosterone, and increased PTH are associated with an increased muscle loss 
Nathan Goodyear

Testosterone deficiency is associated with increased risk of mortality and testosterone... - 0 views

www.eje-online.org/...725.full

low T Testosterone mortality Diabetes therapy treatment men male hormone hormones

shared by Nathan Goodyear on 19 Feb 14 - No Cached
  • Nathan Goodyear on 19 Feb 14
     
    Men with type II diabetes have lower Testosterone levels when compared to none diabetics.  This study found an increased mortality with low T in those with type II Diabetes.  The main association was found with bioavailable Testosterone.  Total Testosterone is proving useless as a functional tool.  Additionally, Testosterone therapy reduced mortality in those with Diabetes.
Nathan Goodyear

[Plasma testosterone, obesity, metabolic syndrome and diabetes]. - Abstract - Europe Pu... - 0 views

europepmc.org/...24268958

low T Testosterone cardiovascular disease metabolic syndrome metabolic syndrome MetS diabetes insulin resistance obesity men male hormones hormone

shared by Nathan Goodyear on 13 Mar 14 - No Cached
  • Nathan Goodyear on 13 Mar 14
     
    Androgen deprivation therapy leads to insulin resistance, metabolic syndrome, and type II diabetes in men. Testosterone therapy in men with IR, obesity, metabolic syndrome, and type II Diabetes will result in improved cardiovascular risk.  
Nathan Goodyear

Testosterone and the Cardiovascular System: A Comprehensive Review of the Clinical Lite... - 0 views

jaha.ahajournals.org/...e000272.full

Testosterone men male cardiovascular disease low T

shared by Nathan Goodyear on 20 Nov 13 - No Cached
  • Low endogenous bioavailable testosterone levels have been shown to be associated with higher rates of all‐cause and cardiovascular‐related mortality.39,41,46–47 Patients suffering from CAD,13–18 CHF,137 T2DM,25–26 and obesity27–28
  • have all been shown to have lower levels of endogenous testosterone compared with those in healthy controls. In addition, the severity of CAD15,17,29–30 and CHF137 correlates with the degree of testosterone deficiency
  • In patients with CHF, testosterone replacement therapy has been shown to significantly improve exercise tolerance while having no effect on LVEF
  • ...66 more annotations...
  • testosterone therapy causes a shift in the skeletal muscle of CHF patients toward a higher concentration of type I muscle fibers
  • Testosterone replacement therapy has also been shown to improve the homeostatic model of insulin resistance and hemoglobin A1c in diabetics26,68–69 and to lower the BMI in obese patients.
  • Lower levels of endogenous testosterone have been associated with longer duration of the QTc interval
  • testosterone replacement has been shown to shorten the QTc interval
  • negative correlation has been demonstrated between endogenous testosterone levels and IMT of the carotid arteries, abdominal aorta, and thoracic aorta
  • These findings suggest that men with lower levels of endogenous testosterone may be at a higher risk of developing atherosclerosis.
  • Current guidelines from the Endocrine Society make no recommendations on whether patients with heart disease should be screened for hypogonadism and do not recommend supplementing patients with heart disease to improve survival.
  • The Massachusetts Male Aging Study also projects ≈481 000 new cases of hypogonadism annually in US men within the same age group
  • since 1993 prescriptions for testosterone, regardless of the formulation, have increased nearly 500%
  • Testosterone levels are lower in patients with chronic illnesses such as end‐stage renal disease, human immunodeficiency virus, chronic obstructive pulmonary disease, type 2 diabetes mellitus (T2DM), obesity, and several genetic conditions such as Klinefelter syndrome
  • A growing body of evidence suggests that men with lower levels of endogenous testosterone are more prone to develop CAD during their lifetimes
  • There are 2 major potential confounding factors that the older studies generally failed to account for. These factors are the subfraction of testosterone used to perform the analysis and the method used to account for subclinical CAD.
  • The biologically inactive form of testosterone is tightly bound to SHBG and is therefore unable to bind to androgen receptors
  • The biologically inactive fraction of testosterone comprises nearly 68% of the total testosterone in human serum
  • The biologically active subfraction of testosterone, also referred to as bioavailable testosterone, is either loosely bound to albumin or circulates freely in the blood, the latter referred to as free testosterone
  • It is estimated that ≈30% of total serum testosterone is bound to albumin, whereas the remaining 1% to 3% circulates as free testosterone
  • it can be argued that using the biologically active form of testosterone to evaluate the association with CAD will produce the most reliable results
  • English et al14 found statistically significant lower levels of bioavailable testosterone, free testosterone, and free androgen index in patients with catheterization‐proven CAD compared with controls with normal coronary arteries
  • patients with catheterization‐proven CAD had statistically significant lower levels of bioavailable testosterone
  • In conclusion, existing evidence suggests that men with CAD have lower levels of endogenous testosterone,13–18 and more specifically lower levels of bioavailable testosterone
  • low testosterone levels are associated with risk factors for CAD such as T2DM25–26 and obesity
  • In a meta‐analysis of these 7 population‐based studies, Araujo et al41 showed a trend toward increased cardiovascular mortality associated with lower levels of total testosterone, but statistical significance was not achieved (RR, 1.25
  • the authors showed that a decrease of 2.1 standard deviations in levels of total testosterone was associated with a 25% increase in the risk of cardiovascular mortality
  • the relative risk of all‐cause mortality in men with lower levels of total testosterone was calculated to be 1.35
  • higher risk of cardiovascular mortality is associated with lower levels of bioavailable testosterone
  • Existing evidence seems to suggest that lower levels of endogenous testosterone are associated with higher rates of all‐cause mortality and cardiovascular mortality
  • studies have shown that lower levels of endogenous bioavailable testosterone are associated with higher rates of all‐cause and cardiovascular mortality
  • It may be possible that using bioavailable testosterone to perform mortality analysis will yield more accurate results because it prevents the biologically inactive subfraction of testosterone from playing a potential confounding role in the analysis
  • The earliest published material on this matter dates to the late 1930s
  • the concept that testosterone replacement therapy improves angina has yet to be proven wrong
  • In more recent studies, 3 randomized, placebo‐controlled trials demonstrated that administration of testosterone improves myocardial ischemia in men with CAD
  • The improvement in myocardial ischemia was shown to occur in response to both acute and chronic testosterone therapy and seemed to be independent of whether an intravenous or transdermal formulation of testosterone was used.
  • testosterone had no effect on endothelial nitric oxide activity
  • There is growing evidence from in vivo animal models and in vitro models that testosterone induces coronary vasodilation by modulating the activity of ion channels, such as potassium and calcium channels, on the surface of vascular smooth muscle cells
  • Experimental studies suggest that the most likely mechanism of action for testosterone on vascular smooth muscle cells is via modulation of action of non‐ATP‐sensitive potassium ion channels, calcium‐activated potassium ion channels, voltage‐sensitive potassium ion channels, and finally L‐type calcium ion channels
  • Corona et al confirmed those results by demonstrating that not only total testosterone levels are lower among diabetics, but also the levels of free testosterone and SHBG are lower in diabetic patients
  • Laaksonen et al65 followed 702 Finnish men for 11 years and demonstrated that men in the lowest quartile of total testosterone, free testosterone, and SHBG were more likely to develop T2DM and metabolic syndrome.
  • Vikan et al followed 1454 Swedish men for 11 years and discovered that men in the highest quartile of total testosterone were significantly less likely to develop T2DM
  • authors demonstrated a statistically significant increase in the incidence of T2DM in subjects receiving gonadotropin‐releasing hormone antagonist therapy. In addition, a significant increase in the rate of myocardial infarction, stroke, sudden cardiac death, and development of cardiovascular disease was noted in patients receiving antiandrogen therapy.67
  • Several authors have demonstrated that the administration of testosterone in diabetic men improves the homeostatic model of insulin resistance, hemoglobin A1c, and fasting plasma glucose
  • Existing evidence strongly suggests that the levels of total and free testosterone are lower among diabetic patients compared with those in nondiabetics
  • insulin seems to be acting as a stimulant for the hypothalamus to secret gonadotropin‐releasing hormone, which consequently results in increased testosterone production. It can be argued that decreased stimulation of the hypothalamus in diabetics secondary to insulin deficiency could result in hypogonadotropic hypogonadism
  • BMI has been shown to be inversely associated with testosterone levels
  • This interaction may be a result of the promotion of lipolysis in abdominal adipose tissue by testosterone, which may in turn cause reduced abdominal adiposity. On the other hand, given that adipose tissue has a higher concentration of the enzyme aromatase, it could be that increased adipose tissue results in more testosterone being converted to estrogen, thereby causing hypogonadism. Third, increased abdominal obesity may cause reduced testosterone secretion by negatively affecting the hypothalamus‐pituitary‐testicular axis. Finally, testosterone may be the key factor in activating the enzyme 11‐hydroxysteroid dehydrogenase in adipose tissue, which transforms glucocorticoids into their inactive form.
  • increasing age may alter the association between testosterone and CRP. Another possible explanation for the association between testosterone level and CRP is central obesity and waist circumference
  • Bai et al have provided convincing evidence that testosterone might be able to shorten the QTc interval by augmenting the activity of slowly activating delayed rectifier potassium channels while simultaneously slowing the activity of L‐type calcium channels
  • consistent evidence that supplemental testosterone shortens the QTc interval.
  • Intima‐media thickness (IMT) of the carotid artery is considered a marker for preclinical atherosclerosis
  • Studies have shown that levels of endogenous testosterone are inversely associated with IMT of the carotid artery,126–128,32,129–130 as well as both the thoracic134 and the abdominal aorta
  • 1 study has demonstrated that lower levels of free testosterone are associated with accelerated progression of carotid artery IMT
  • another study has reported that decreased levels of total and bioavailable testosterone are associated with progression of atherosclerosis in the abdominal aorta
  • These findings suggest that normal physiologic testosterone levels may help to protect men from the development of atherosclerosis
  • Czesla et al successfully demonstrated that the muscle specimens that were exposed to metenolone had a significant shift in their composition toward type I muscle fibers
  • Type I muscle fibers, also known as slow‐twitch or oxidative fibers, are associated with enhanced strength and physical capability
  • It has been shown that those with advanced CHF have a higher percentage of type II muscle fibers, based on muscle biopsy
  • Studies have shown that men with CHF suffer from reduced levels of total and free testosterone.137 It has also been shown that reduced testosterone levels in men with CHF portends a poor prognosis and is associated with increased CHF mortality.138 Reduced testosterone has also been shown to correlate negatively with exercise capacity in CHF patients.
  • Testosterone replacement therapy has been shown to significantly improve exercise capacity, without affecting LVEF
  • the results of the 3 meta‐analyses seem to indicate that testosterone replacement therapy does not cause an increase in the rate of adverse cardiovascular events
  • Data from 3 meta‐analyses seem to contradict the commonly held belief that testosterone administration may increase the risk of developing prostate cancer
  • One meta‐analysis reported an increase in all prostate‐related adverse events with testosterone administration.146 However, when each prostate‐related event, including prostate cancer and a rise in PSA, was analyzed separately, no differences were observed between the testosterone group and the placebo group
  • the existing data from the 3 meta‐analyses seem to indicate that testosterone replacement therapy does not increase the risk of adverse cardiovascular events
  • the authors correctly point out the weaknesses of their study which include retrospective study design and lack of randomization, small sample size at extremes of follow‐up, lack of outcome validation by chart review and poor generalizability of the results given that only male veterans with CAD were included in this study
    • Nathan Goodyear
      Nathan Goodyear on 04 Dec 13
       
      The authors here present Total Testosterone as a "confounding" value
    • Nathan Goodyear
      Nathan Goodyear on 09 Dec 13
       
      This would be HSD-II
  • the studies that failed to find an association between testosterone and CRP used an older population group
  • low testosterone may influence the severity of CAD by adversely affecting the mediators of the inflammatory response such as high‐sensitivity C‐reactive protein, interleukin‐6, and tumor necrosis factor–α
  • Nathan Goodyear on 20 Nov 13
     
    Good review of Testosterone and CHD.  Low T is associated with increased all cause mortality and cardiovascular mortality, CAD, CHF, type II diabetes, obesity, increased IMT,  increased severity of CAD and CHF.  Testosterone replacement in men with low T has been shown to improve exercise tolerance in CHF, improve insulin resistance, improve HgbA1c and lower BMI in the obese.
Nathan Goodyear

Caffeinated and Decaffeinated Coffee Consumption and Risk of Type 2 Diabetes: A Systema... - 0 views

care.diabetesjournals.org/...569.abstract

coffee diabetes type II diabetes type II DM polyphenol

shared by Nathan Goodyear on 03 Apr 14 - No Cached
  • Nathan Goodyear on 03 Apr 14
     
    Coffee, whether caffeinated or decaffeinated, is found to reduce the risk of type II diabetes in meta-analysis.  According to the authors, it is the polyphenols that provide the benefits.
Nathan Goodyear

Hypogonadism and Metabolic Syndrome in Nigerian Male Patients With Both Type 2 Diabetes... - 0 views

www.ncbi.nlm.nih.gov/...PMC3968985

diabetes hypertension blood pressure metabolic syndrome low T Testosterone CVD men male hormone hormones lipids dyslipidemia

shared by Nathan Goodyear on 07 Apr 14 - No Cached
  • Nathan Goodyear on 07 Apr 14
     
    Asian study finds Testosterone is inversely associated with increased central obesity, increased dyslipidemia, and metabolic syndrome in me with new diagnosis of type II diabetes and hypertension.  Men with metabolic syndrome, type II diabetes, and CVD must have appropriate hormone evaluation.
Nathan Goodyear

Effect of Testosterone Treatment on Glucose Metabolism in Men With Type 2 Diabetes: A R... - 0 views

care.diabetesjournals.org/...2098.abstract

Testosterone treatment low subcutaneous fat visceral fat T glucose insulin resistance metabolism obesity diabetes men male hormone hormones

shared by Nathan Goodyear on 29 Jul 14 - No Cached
  • Nathan Goodyear on 29 Jul 14
     
    Only the abstract available in this publication.  Good study design.  No improvement in insulin resistance, glycemic control or visceral adiposity in obese men with type II diabetes.  The levels of inclusion were TT < 346, which would not meet the criteria put forth by other studies.  This study appeared to look at border line "low T" men with obesity and type II diabetes and found no direct glycemic control improvement.  An increase in lean muscle mass and decrease in subcutaneous fat was found.
Nathan Goodyear

The Evaluation of Serum Levels of Testosterone in Type 2 Diabetic Men and Its Relation ... - 0 views

www.ncbi.nlm.nih.gov/...PMC4347063

low t low Testosterone total testosterone free testosterone glucose cholesterol LDL HgbA1c SHBG Testosterone men male hormone diabetes

shared by Nathan Goodyear on 10 Mar 15 - No Cached
  • Nathan Goodyear on 10 Mar 15
     
    Small study of 2 men with type II diabetes finds fasting glucose levels negatively correlate with total and free Testosterone levels, HgbA1c negatively correlated with SHBG only, total cholesterol and LDL negatively correlated with SHBG and total testosterone.  The prevalence of type II diabetes was higher with low free Testosterone than total Testosterone, but both were statistically significant.
Nathan Goodyear

Unintended effects of statins from observational studies in the general population: sys... - 0 views

www.ncbi.nlm.nih.gov/...PMC3998050

statin therapy statins myopathy cholesterol side effects diabetes liver liver enzymes

shared by Nathan Goodyear on 19 Mar 15 - No Cached
  • A markedly increased risk of myopathy was observed
  • One cohort study (Women’s Health Initiative) of higher quality and larger sample size found stronger evidence of an increased risk of self-reported T2DM (OR=1.47; 95% CI 1.32 to 1.64) for the groups of women who reported statin use at baseline and three years later
  • Hippisley-Cox et al. found an increased risk of liver enzyme changes
  • ...5 more annotations...
  • weak evidence of an increased risk of type 2 diabetes mellitus (T2DM) was observed
  • Smeeth et al. found an increased risk of incident liver disease in the first year after the index date
  • The cumulative incidence of T2DM after three years of statin treatment was 6.25%, corresponding to an excess risk of 2.25%
  • We found no increased risk of peripheral neuropathy, depression, common eye diseases, renal disorders or arthritis associated with taking statins. Studies of higher quality did not show previously reported protective effects of statins on fractures, venous thrombo-embolism or pneumonia
  • There was evidence of an increase in myopathy, raised liver enzymes and diabetes.
  • Nathan Goodyear on 19 Mar 15
     
    Statin use associated with increased myopathy, liver dysfunction, and type II Diabetes.  The authors conclude that the absolute risk is very low, yet OR was 1.47 for type II Diabetes (translated 47% increased odds of developing Diabetes as a result of statins) and OR of 2.63 in risk of myopathy (translated 163% increased odds of developing myopathy as a result of statins).  Seems the authors "low risk" statement is just applies to those without symptoms/side effects.  Physicians need to do a better job of understanding risks and customizing therapies.
Nathan Goodyear

Colonic Microbiota Encroachment Correlates With Dysglycemia in Humans - Cellular and Mo... - 0 views

www.cmghjournal.org/...fulltext

'metabolic endotoxemia gut gut bacteria insulin resistance diabetes

shared by Nathan Goodyear on 12 Jun 17 - No Cached
  • most (86%) were overweight, many (45%) were obese
  • third (14 out of 42) had diabetes
  • in obese persons with diabetes, bacteria could be found in the dense inner mucus and in close proximity to the epithelium
  • Nathan Goodyear on 12 Jun 17
     
    Gut bacteria proximity, not just balance and diversity, to mucosa lining linked to systemic inflammation and insulin resistance in type II diabetes.  The role of type II diabetes may simply be the gut.  This has been called metabolic endotoxemia.
Nathan Goodyear

Surgically induced accelerated local and distant tumor growth is significantly attenuat... - 0 views

pubmed.ncbi.nlm.nih.gov/15734421

cancer metastasis surgery

shared by Nathan Goodyear on 13 Aug 20 - No Cached
  • Nathan Goodyear on 13 Aug 20
     
    Cox II inhibition helps to slow surgical induced metastatic and local recurrence of cancer. Surgery does cause metastasis and local recurrence and cox II inhibition stops spread.
Nathan Goodyear

Biochemical and metabolic mechanisms by which... [J Nutr Biochem. 2012] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...22995389

whey protein obesity metabolic syndrome type II DM diabetes

shared by Nathan Goodyear on 24 Sep 12 - No Cached
  • Nathan Goodyear on 24 Sep 12
     
    Whey protein should be a tool in every medical provider to combat obesity and type II Diabetes.  The role? through improved insulin function: by interactions with cholecystokinin, peptide YY, incretins...
1 - 20 of 215 Next › Last »
Showing 20▼ items per page